A single intradiscal injection of SI-6603 demonstrated significantly greater improvement in leg pain vs. sham at Week 13 in a…
Results of a Phase 3 study show durable complete response in evaluation of high-grade recurrence-free survival, cystectomy-free survival, and overall…
Parsippany, NJ – February 27, 2024 – Ferring stands with the American Society for Reproductive Medicine, RESOLVE: The National Infertility…
Ferring presenting design and methodology for the ABLE-41 Real-World Evidence study at this week’s 20th Annual ASCO Genitourinary Cancers Symposium…
Patients with high-risk, non-muscle invasive bladder cancer now have greater access to the first and only FDA-approved intravesical gene therapy…
Ferring Pharmaceuticals’ Fertility Out Loud Docuseries follows four U.S.-based couples as they face their unique fertility journeys head-on Episode one…
36-month follow-up data from the Phase 3 study demonstrate one-quarter of patients with high-risk, BCG-unresponsive NMIBC remained free of high-grade…
Parsippany, NJ – November 15, 2023 – Ferring Pharmaceuticals appreciates the ongoing support from New Jersey and Minnesota as both…
New analysis evaluates the association between gut microbiome composition and health-related quality of life for patients with recurrent C. diff…
“Transformational” Gift will Establish the “Ferring Endowment for the Education of Healthcare Professionals in Training” Washington, DC and Parsippany, NJ…